Astellas Pharma: Tender Offer For OSI Successful
03 Junio 2010 - 2:40AM
Noticias Dow Jones
Astellas Pharma Inc. (4503.TO) said Thursday it received enough
offers of shares in U.S. cancer drug developer OSI Pharmaceuticals
Inc. (OSIP) to complete its takeover of the company, a deal that
could be worth up to $4.0 billion.
The Tokyo-based drug maker said the number of OSI shares offered
by shareholders during the tender period through Wednesday was
equivalent to 87% of the company's outstanding stocks, including
those to be offered within three business days under the process
known as guaranteed delivery.
The tender offer, which started as a hostile takeover attempt in
early March, has been repeatedly extended as OSI sought bids higher
than Astellas' initial offer of $52 a share.
Astellas and OSI agreed on the acquisition after the Japanese
company raised the offer to $57.50 on May 17. OSI shares ended at
$57.42 Wednesday on the Nasdaq Stock Market.
-By Kazuhiro Shimamura, Dow Jones Newswires; 813-6269-2790;
kazuhiro.shimamura@dowjones.com
Osi Pharmaceuticals (NASDAQ:OSIP)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Osi Pharmaceuticals (NASDAQ:OSIP)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Osi Pharmaceuticals Inc. (MM) (NASDAQ): 0 recent articles
Más de OSI Pharmaceuticals Inc. Artículos de Noticias